{"id":22034,"date":"2024-09-23T11:14:49","date_gmt":"2024-09-23T11:14:49","guid":{"rendered":"https:\/\/clinlabint.com\/?p=22034"},"modified":"2024-09-23T11:14:49","modified_gmt":"2024-09-23T11:14:49","slug":"sgs-expands-specialised-bioanalytical-testing-services-to-north-american-market","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/sgs-expands-specialised-bioanalytical-testing-services-to-north-american-market\/","title":{"rendered":"SGS expands specialised bioanalytical testing services to North American market"},"content":{"rendered":"
\n

\r\n\"Bio-Rad<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

SGS expands specialised bioanalytical testing services to North American market<\/h1>\/ in E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

SGS, a global leader in testing, inspection, and certification, has announced the introduction of new specialised bioanalytical testing services for the North American pharmaceutical and biopharmaceutical markets. This expansion marks a significant development in the company’s capabilities to support drug development processes across various clinical trial phases.<\/h3>\n

<\/p>\n

State-of-the-art facility<\/strong>
\nThe new services will be delivered from SGS’s advanced laboratory in Hudson, New Hampshire, strategically located near the Boston Massachusetts Biotech Hub. This facility is now equipped to offer comprehensive bioanalytical solutions supporting discovery, pre-clinical, and phase 1-3 clinical trials.<\/p>\n

The range of services includes:
\n\u2022 Method transfer and development
\n\u2022 Validation
\n\u2022 Pharmacodynamic (PD) bioanalysis
\n\u2022 Pharmacokinetic (PK) bioanalysis
\n\u2022 Immunogenicity testing
\n\u2022 ELISA and multiplex assays
\n\u2022 Bioassays<\/p>\n

This expansion leverages SGS’s global partnership with Agilex Biolabs, Australian bioanalytical testing specialists. The addition of the Hudson laboratory complements SGS’s existing global network of bioanalytical labs in France, Belgium, Switzerland, Germany, and Shanghai.<\/p>\n

Derick Govender, Head of North America at SGS, commented on the expansion: “This is an exciting development for SGS, as we continue to expand our service offering to US and international markets. The introduction of this new specialised capability allows us to provide seamless bioanalytical testing services across phase 1 to phase 3 of the pre-clinical and clinical drug development process.”<\/p>\n

Comprehensive quality control testing<\/strong>
\nWith over three decades of experience in the pharmaceutical industry, SGS offers extensive quality control testing for raw materials, active pharmaceutical ingredients (APIs), and finished products, supporting both small and large molecule drug products. The new services at the Hudson facility complete SGS’s network of bioanalytical service centres, enabling global support for clinical trials.<\/p>\n

Regulatory compliance and global reach<\/strong>
\nSGS operates 20 laboratories across 11 countries, all fully compliant with the highest regulatory standards. This extensive network positions SGS as a leading choice for manufacturers and developers in the pharmaceutical and biopharmaceutical industries.<\/p>\n

The company’s global presence includes 99,600 employees operating a network of 2,600 offices and laboratories worldwide, reinforcing its position as a global benchmark for sustainability, quality, and integrity in the testing, inspection, and certification sector.<\/p>\n

This expansion of bioanalytical testing services in North America represents a significant enhancement to the drug development infrastructure in the region. By providing a comprehensive suite of services from discovery through to late-phase clinical trials, SGS is poised to accelerate and streamline the drug development process for pharmaceutical and biopharmaceutical companies.<\/p>\n<\/div><\/section>
\n

\"\"<\/div><\/div><\/div>
\n

Derick Govender, Head of North America at SGS<\/strong><\/em><\/p>\n<\/div><\/section>
\n